Journal of Antimicrobial Chemotherapy (1999) 44, 483-488
© 1999 The British Society for Antimicrobial Chemotherapy
Aminoglycoside resistance in Gram-negative blood isolates from various hospitals in Belgium and the Grand Duchy of Luxembourg
a Unit of Antibiotic Research, Pasteur Institute Brussels, Engelandstraat 642, B-1180, Brussels, Belgium
A total of 1102 consecutive clinical blood isolates, including 897 Enterobacteriaceae and 205 non-fermenting bacilli, were obtained from 13 university and university-affiliated hospitals, which were divided into a Northern and a Southern group. Resistance to gentamicin, tobramycin, netilmicin, amikacin and isepamicin was determined using a microdilution technique according to NCCLS procedures. The overall mean resistance level was 5.9% for gentamicin, 7.7% for tobramycin, 7.5% for netilmicin, 2.8% for amikacin and 1.2% for isepamicin. Resistance to amikacin and isepamicin was significantly higher in the Northern hospitals than in the Southern hospitals. In total, 157 isolates were found not to be susceptible to aminoglycosides. By PCR, 179 aminoglycoside resistance mechanisms, i.e. 150 genes encoding modifying enzymes and 29 permeability mechanisms, were detected in 148 isolates. A resistance mechanism could not be detected in nine isolates. Moreover, in a further 14 isolates the resistance profile was not fully explained by the detected genes. The aac(6')-I genes were found to be the most predominant resistance mechanism in both the Northern and Southern isolates, followed by aac(3)genes and permeability resistance. A total of 29 non-susceptible isolates harboured a combination of genes, 72.4% of which were a combination with the aac(6')-Ib gene. The majority of these combinations were broad-spectrum combinations which represented 9.0% of the resistance mechanisms in non-susceptible Enterobacteriaceae and 19.3% in the non-fermenting bacilli.
* Corresponding author. Tel: +32-2-373-32-61. Fax: +32-2-373-32-78.
Participants. M. Carpentier (Liège), M. Delmee (brussels),
P. De Mol (Liège), M.-G. Garrino (mont Godinne), H. Gossens (antwerp), Y.
glupczynski (montigny-le-Tilleul), R. Hemmer (Luxembourg), S. Lauwers (brussels), F. Meunier
(Jolimont), M. Struelens (Brussels), H. Van Landuyt (Brugge), L. Verbist (Leuven) and G.
Verscyhraegen (Ghent).
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Dubois, C. Arpin, V. Dupart, A. Scavelli, L. Coulange, C. Andre, I. Fischer, F. Grobost, J.-P. Brochet, I. Lagrange, et al. {beta}-Lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres) J. Antimicrob. Chemother., August 1, 2008; 62(2): 316 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hocquet, P. Berthelot, M. Roussel-Delvallez, R. Favre, K. Jeannot, O. Bajolet, N. Marty, F. Grattard, P. Mariani-Kurkdjian, E. Bingen, et al. Pseudomonas aeruginosa May Accumulate Drug Resistance Mechanisms without Losing Its Ability To Cause Bloodstream Infections Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3531 - 3536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bogaerts, M. Galimand, C. Bauraing, A. Deplano, R. Vanhoof, R. De Mendonca, H. Rodriguez-Villalobos, M. Struelens, and Y. Glupczynski Emergence of ArmA and RmtB aminoglycoside resistance 16S rRNA methylases in Belgium J. Antimicrob. Chemother., March 1, 2007; 59(3): 459 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. De Gheldre, M. J. Struelens, Y. Glupczynski, P. De Mol, N. Maes, C. Nonhoff, H. Chetoui, C. Sion, O. Ronveaux, and M. Vaneechoutte National Epidemiologic Surveys of Enterobacter aerogenes in Belgian Hospitals from 1996 to 1998 J. Clin. Microbiol., March 1, 2001; 39(3): 889 - 896. [Abstract] [Full Text]
|
|